This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Alzheimer's disease (AD)	β -Amyloid (A β)	<i>In silico</i> and <i>in vitro</i> studies identified A β fiber-binding compounds that could help treat AD. In a structure-based computational screen of 18,000 compounds for A β fiber binding, the 25 top-ranked hits were selected for experimental validation. In binding assays and human cell lines, eight hits bound A β fibers and decreased A β -associated cytotoxicity compared with no treatment. Next steps include evaluating the lead compounds in additional cellular and animal models of AD.	Patent application filed; licensed	Jiang, L. <i>et al. eLife</i> ; published online July 16, 2013; doi:10.7554/eLife.00857 Contact: David S. Eisenberg, University of California, Los Angeles, Calif. e-mail: david@mbi.ucla.edu
<i>SciBX</i> 6(33); doi:10.1038/scibx.2013.897 Published online Aug. 29, 2013				